1-4 of 4
Wei Mu
Close
Sort by
Journal Articles

Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma

Jiali Cheng, Jue Wang, Xia Mao, Wei Mu, Shijia Sun, Xiaoxi Zhou, Liang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6863.
https://doi.org/10.1182/blood-2023-184370
Published: 2023
Journal Articles

Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

Chunrui Li, Di Wang, Qiuxia Yu, Zhe Li, Wen Wang, Guang Hu, Wei Mu, Chunhui Li, Ning An, Xiaolu Long, Yuhan Bao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4854.
https://doi.org/10.1182/blood-2023-181394
Published: 2023
Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Zongcheng Li, Lei Zhao, Yuanyuan Zhang, Li Zhu, Wei Mu, Tong Ge, Jin Jin, Jiaqi Tan, Jiali Cheng, Jue Wang, Na Wang, Xiaoxi Zhou, Liting Chen, Zhilin Chang, Chen Liu, Bian Zhilei, Bing Liu, Lilin Ye, Yu Lan, Liang Huang, Jianfeng Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 4851.
https://doi.org/10.1182/blood-2023-178624
Published: 2023
Journal Articles

Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host

Yuhang Cheng, Jiayuan Zhang, Xiaoqian Wang, Wenjie Dong, Xiaomin Yao, Yage Zhang, Juan Yang, Wei Mu, Jue Wang, Liang Huang, Guang Hu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4556–4557.
https://doi.org/10.1182/blood-2022-169039
Published: 2022